Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /FDA /BRIEF—Opdivo first FDA-approved PD-1 inhibitor to offer every four-wee

BRIEF—Opdivo first FDA-approved PD-1 inhibitor to offer every four-wee

by JMC on March 6, 2018

The US Food and Drug Administration has approved Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab) dosing schedule to include 480mg infused every four weeks (Q4W) for a majority of approved indications in the treatment of various cancers.

This approval will provide health care professionals the flexibility to customize patient care with the option of using the newly approved Q4W (480mg) flat dose in addition to the previously available option of every two weeks (Q2W) at 240mg, now available in a new 240mg vial.

Opdivo was also approved for a shorter 30-minute infusion across all approved indications.

Dosing schedule updates for an additional approvedindication for Opdivo may be submitted to the FDA in the future, said B-MS.

Source: BRIEF—Opdivo first FDA-approved PD-1 inhibitor to offer every four-wee

Previous post:

Next post: